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Abstract
Background: Patellar tendinopathy is one of the leading causes of tendon related injuries affecting active
individuals. Because of the chronic nature of tendinopathy, traditional measures aimed at treating
inflammation have not been effective. Platelet-rich plasma (PRP) has gained favor because of the theorized
ability to accelerate tissue healing and regeneration. Will the injection of PRP be an effective treatment for
patellar tendinopathy?
Methods: An exhaustive literature search was performed using Medline, Web of Knowledge, SPORTDiscus,
CINAHL, and the NIH clinical trials site using the keywords: platelet-rich plasma and tendinopathy. The
selected articles were analyzed for quality using the Grading of Recommendations, Assessment, Development
and Evaluation (GRADE).
Results: Four studies were included that met inclusion and exclusion criteria. A randomized control trial with
23 patients treated with PRP showed superior Victorian Institute of Sport Assessment – Patellar questionnaire
(VISA-P) score improvements as compared to 23 patients treated with extracorporeal shock wave therapy at 6
and 12 months follow-up. A prospective cohort followed 43 patients and showed stable improvements in
VISA-P at 2, 6, and 84 month follow-up. One prospective cohort analyzed 14 patients who had prior injection
and/or surgical treatment with 22 patients who had not received any injection or surgical treatment before.
Both treatment groups had decreased pain, but the group who had not received prior treatments showed
improved VISA-P. Another prospective cohort examined 24 patients at 20 days post injection and 6 months
post injection. No significant improvement was seen at 20 days, but VISA-P did improve at the 6 month
follow-up.
Conclusion: The use of PRP for treating patellar tendinopathy has shown to be effective in these studies by
increasing VISA-P. To date, no randomized control trials comparing PRP to saline or dry-needling have been
conducted. Thus, future research should focus on identifying proper treatment time, optimal dosage and
number of injections, and ideal PRP concentration.
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Abstract   
 
Background:  Patellar tendinopathy is one of the leading causes of tendon related 
injuries affecting active individuals.  Because of the chronic nature of tendinopathy, 
traditional measures aimed at treating inflammation have not been effective.  Platelet-rich 
plasma (PRP) has gained favor because of the theorized ability to accelerate tissue 
healing and regeneration.  Will the injection of PRP be an effective treatment for patellar 
tendinopathy? 
 
Methods:  An exhaustive literature search was performed using Medline, Web of 
Knowledge, SPORTDiscus, CINAHL, and the NIH clinical trials site using the 
keywords: platelet-rich plasma and tendinopathy. The selected articles were analyzed for 
quality using the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE).  
 
Results:  Four studies were included that met inclusion and exclusion criteria.  A 
randomized control trial with 23 patients treated with PRP showed superior Victorian 
Institute of Sport Assessment – Patellar questionnaire (VISA-P) score improvements as 
compared to 23 patients treated with extracorporeal shock wave therapy at 6 and 12 
months follow-up.  A prospective cohort followed 43 patients and showed stable 
improvements in VISA-P at 2, 6, and 84 month follow-up.  One prospective cohort 
analyzed 14 patients who had prior injection and/or surgical treatment with 22 patients 
who had not received any injection or surgical treatment before.  Both treatment groups 
had decreased pain, but the group who had not received prior treatments showed 
improved VISA-P.  Another prospective cohort examined 24 patients at 20 days post 
injection and 6 months post injection.  No significant improvement was seen at 20 days, 
but VISA-P did improve at the 6 month follow-up. 
 
Conclusion:  The use of PRP for treating patellar tendinopathy has shown to be effective 
in these studies by increasing VISA-P.  To date, no randomized control trials comparing 
PRP to saline or dry-needling have been conducted.  Thus, future research should focus 
on identifying proper treatment time, optimal dosage and number of injections, and ideal 
PRP concentration. 
 
Keywords:  platelet-rich plasma, injections, patella, tendinopathy, and jumper’s knee 
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The Efficacy of Platelet-rich Plasma Injection in the Treatment 
of Patellar Tendinopathy 
 
BACKGROUND 
According to the National Center for Health Statistic National Health Interview 
Survey1 conducted in 2008, musculoskeletal disorders and diseases are the leading cause 
of physical disability in the United States. Tendon related injuries account for 
approximately 30-50% of sports related injuries.2  Patellar tendinopathy, or jumper’s 
knee, among non-elite athletes has been reported at 8.5% with a 2:1 ratio of men to 
women3 while elite athletes have a slightly higher percentage at 14.2%.4   
Patellar tendinopathy is one of the most common tendon injuries and is marked by 
tenderness at the superior or inferior pole of the patella.5  Tendinopathy describes the 
degeneration seen in the tendon due to disordered healing in the absence of 
inflammation.6 Pain associated with jumper’s knee is difficult to quantify, thus the need 
for a validated and widely used assessment tool that allows practitioners to reliably assess 
a patient’s symptoms, function, and ability to undertake physical activity.  The Victorian 
Institute of Sport Assessment – Patellar questionnaire (VISA-P) is the only published 
clinical scale validated for patellar tendinopathy.  The VISA-P is comprised of eight 
questions, six of which are scored on a visual analogue scale from 0-10 with 10 
representing optimal health.7  See Appendix. 
Standard of care treatment options for jumper’s knee includes rest, ice, non-
steroid anti-inflammatory drugs, and eccentric based exercise programs.8-12 Various 
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injections and surgery are utilized once conservative measures have failed.10,13  Recently, 
the use platelet-rich plasma (PRP) for tendon healing has gained popularity due to its 
potential ability to regenerate tissue and accelerate the body’s healing process.14 
  PRP is an autologous product that has been utilized and studied since the 1970’s 
in many fields.15  PRP is made from anticoagulated blood that has been centrifuged to 
increase the concentration of platelets compared to whole blood.16 Platelets are the first 
cell to arrive at an injury site to begin hemostasis through cell membrane adherence, 
aggregation, and clot formation.  During degranulation, they release growth factors, 
cytokines, and bioactive proteins that enhance and regulate tissue healing.15,17-19 The aim 
of this review is to assess the efficacy of platelet-rich plasma for the treatment of patellar 
tendinopathy. 
METHODS 
An exhaustive literature search was performed using Medline, Web of 
Knowledge, SPORTDiscus, CINAHL, and the NIH clinical trials site using the search 
terms “platelet-rich plasma” and “tendinopathy.”  A cited reference search was also 
utilized to find relevant sources.  Results were then narrowed to include only articles in 
the English language, on human subjects, and published since 2012.  Only articles that 
utilized PRP for use in treating patellar tendinopathy were included.  Studies were also 
excluded if they did not utilize the VISA-P as a means for measuring outcomes.  The 
selected articles were analyzed for quality using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE).20 
 - 9 -  
RESULTS 
The initial result of the search yielded 160 articles for review.  A total of four 
relevant articles remained after screening with inclusion and exclusion criteria.  These 
articles included one randomized control trial21 and three prospective observational 
studies.22-24 Table I provides a summary of the studies that were included in the 
systematic review. A search on the NIH clinical trials site reveals 109 current studies 
being conducted on the use of Platelet-rich plasma, three of these trials are randomized 
control trials that are in various stages of enrolling or recruiting. 
Vetrano et al Trial 
Patient Selection—This randomized control trial21 was conducted to compare the 
effectiveness and safety of PRP injections and extracorporeal shock wave therapy 
(ESWT) in athletes with jumper’s knee.  Primary outcomes were defined as an 
improvement of VISA-P score.  Forty-six patients were randomly allocated to receive 
one of two treatments via computer-generated randomization.  Each of the recruited 
patients had the diagnosis of jumper’s knee confirmed by the same clinician as well as 
undergoing ultrasound (US) examination.  Only patients with chronic unilateral 
tendinopathy at the insertion of the patellar tendon at the lower pole of the patella were 
included in this study.  Additional inclusion criteria regarded having the diagnosis for at 
least 6 months before treatment, failure of non-operative management, a 12 week 
washout period between any non-operative therapy and beginning this study, participants 
aged 18 to 50 years, and patients being involved in sporting activities as either an elite or 
non-elite athlete. Exclusion criteria included patients with bilateral complaints, with 
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coexisting knee lesions, with a history of knee surgery or injection therapy with 
corticosteroids in the past 3 months, with systemic disorders, on current anticoagulation 
therapy, a platelet value less than 150,000/mm3, or who are pregnant.  The two groups 
were equivalent in all baseline patient characteristics.  Additionally, the authors note that 
no patients were lost to follow up or had undergone any surgical intervention during the 
follow-up period of 12 months.21 
PRP Preparation—PRP was obtained by a single centrifugation of whole blood to 
isolate platelet using MyCells Autologous Platelet Preparation System.  There was 10ml 
of venous blood collected and mixed with acid-citrate-dextrose to prevent early clotting.  
The blood was then centrifuged for 10 minutes at 1300 to 1500rpm to garner a mean 
platelet concentration of 0.89 to 1.1 X 109 ml which is 3 to 5 times baseline 
concentration.  Then 1ml of this PRP was sent to the laboratory for analysis of platelet 
concentration while the remaining 3 to 5ml was used for patient injection without 
activation.21 
PRP Injection—Patient’s received two autologous PRP injections under US guidance 
over 2 weeks by the same clinician.  A 22-g needle was inserted into the designated 
location via a single skin portal.  Approximately 2ml of PRP was then injected under 
color Doppler guidance placing multiple small aliquots into the tendinous lesion with no 
local anesthesia being applied.21 
Post Injection Protocol—Patients rested in a supine position for 15 minutes without 
moving the leg.  Full weight bearing of the limb was tolerated as well as normal daily 
activities.  One week after the final treatment, patients were given a standardized 
stretching and muscle strengthening protocol to be adhered to for 2 weeks.21 
 - 11 -  
Patient Outcomes—Both treatments (PRP and ESWT) were effective in improving 
VISA-P throughout the study, however, PRP showed greater improvements at the 6 
month and 12 month follow-up.  VISA-P at baseline, 2 months, and 12 months was 55.3, 
76.2, and 91.3, respectively.  For ESWT, these same measurements were 56.1, 71.3, and 
77.6, respectively. See Table I. In addition to an improved VISA-P, after 12 months 
patients who received PRP reported a 91.3% (21/23) level of satisfaction as compared to 
only 60.8% (14/23) for ESWT.21  
The authors note several limitations to their study.  These limitations include a small 
patient enrollment, lack of placebo control group, and use of qualitative outcome 
measures rather than clinical and instrumental measurements (eg, color US and MRI).  
Additionally, the authors report no clinically relevant side effects of either treatment.21 
Filardo et al Trial 
Patient Selection—This prospective study22 was evaluating the therapeutic effects of 
multiple PRP injections at medium-term follow-up by showing the quality and duration 
of clinical improvement as seen with the VISA-P.  Forty-three patients affected by 
chronic patellar proximal tendinopathy were enrolled, 11 of these patients were affected 
bilaterally for a total of 54 patellar tendon treatments.  Inclusion criteria were: exercise-
associated pain for greater than 3 months, pain or tenderness on palpation, and 
degenerative changes in the patella tendon on either MRI or US.22 
PRP Preparation—150ml of venous blood was collected and centrifuged two times.  
The first centrifuge ran at 1480 rpm for 6 minutes to separate the erythrocytes, the second 
ran at 3400 rpm for 15 minutes to concentrate the platelets.  The sample was then divided 
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into four equal parts of 5ml.  One unit was sent to the laboratory for quality control, two 
of the units were stored for later use at -30 C, while the final unit was used for the first 
injection within 2 hours of collection.22 
PRP Injection—Patients underwent three US guided intra-tendinous injections of 5ml 
PRP, two weeks apart.  Prior to administration of the 2nd and 3rd units, the samples were 
thawed and injected with 10% calcium chloride to activate the platelets.  A 22-g needle 
was then inserted under US control directly into the lesion site with multiple penetrations 
of the tendon.22 
Post Injection Protocol—Patients were instructed to begin a rehabilitation program 
between the 2nd and 3rd injections based on eccentric exercises to be implemented for 12 
weeks.22 
Patient Outcomes—Patients reported an improvement in VISA-P over the course of the 
study.  VISA-P increased from 44.1 at baseline to 61.4 at 2 months, 76.6 at 6 months, and 
84.3 at four years’ follow up.  There was 79.1% of the patients satisfied with the 
treatment and would repeat the treatment if needed, while 81.4% returned to previous 
sports activities.  Patients affected by bilateral pathology and presenting with a long 
history of pain obtained significantly poorer results.  However, the patient characteristics 
of age, BMI, previous conservative or surgical treatment did not influence the results in 
this study.22 
Limitations listed by the authors include lack of a randomized control group and only 
performing imaging evaluations on some of the patients rather than all at various points 
throughout follow-up.22 
Gosens et al Trial 
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Patient Selection—Another prospective cohort study23 was conducted to evaluate the 
outcome of patients with patellar tendinopathy treated with PRP, and whether certain 
characteristics, such as activity level and previous treatment affected the outcome.  
Thirty-six patients with chronic patellar tendinopathy were assigned to two treatment 
groups based on prior treatments.  Group 1 was comprised of 14 patients who had 
previously been treated with cortisone, ethoxysclerol and/or surgical treatment, while 
Group 2 had 22 patients who had not received an injection or surgical treatment before.  
Both treatment groups had been through physical therapy and performed eccentric 
exercises before entering the study.  Diagnosis was made on clinical grounds as well as 
an MRI showing edema at the origin of the patellar tendon in 21 (58.3%) of the cases.  
No other inclusion or exclusion criteria were noted by the authors.  At baseline, the two 
groups did not differ in regards to demographic or clinical characteristics.23 
PRP Preparation—27ml of whole blood was collected and placed in a syringe with 3ml 
sodium citrate.  The preparation was then made according to manufacturer instructions 
for the Recover System (Biomet Biologics, Warsaw, Indiana) and then spun at a speed of 
3200 RPM for 15 minutes.  3ml of PRP was obtained for each patient, with the PRP 
begin buffered to a physiological pH using 8.4% sodium bicarbonate and Bupivacaine 
HCL 0.5% with epinehphrine (1:200000) was added.  No activating agent was used.23 
PRP Injection—Using a 22-g needed, 1ml of the prepared PRP was injected into the 
area of maximal tenderness, while the remaining 2ml of PRP was injected into the 
patellar tendon origin on the patella utilizing a “peppering technique” which involves a 
single skin portal and then five penetrations of the tendon.23 
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Post Injection Protocol—Patient’s rested in a supine position without moving the leg for 
15 minutes after the injection, they were then sent home with instructions to rest the leg 
for an additional 24 hours.  After 24 hours, the patients were to start a standardized 
stretching protocol to follow for an additional 2 weeks, after which an eccentric focused 
muscle and tendon strengthening program would begin.23 
Patient Outcomes—The results did show a statistically significant improvement from 
baseline to follow-up after treatment with PRP in regards to VISA-P. However, patients 
who had no prior treatments showed a greater improvement.  Patients completed the 
VISA-P at baseline and at a mean follow-up period of 18.4 months.  The mean VISA-P 
for Group 1 improved from 40.1at baseline to 57.7, while patients in Group 2 increased 
from 39.1 to 58.6.23 
Ferrero et al Trial 
Patient Selection—A prospective cohort24 evaluated 28 patellar tendons in 24 patients 
for the effectiveness of US-guided PRP injection to treat jumper’s knee.  Inclusion 
criteria were the presence of patellar tendinopathy, pain at palpation and during physical 
activity for a minimum of 3 months as well as US or MRI evidence of tendon 
degeneration.  Patients were between the ages of 21 and 57 who had previously utilized 
other treatments with unsatisfactory outcomes.  Exclusion criteria were systemic disease, 
antiplatelet therapy in progress, intake of NSAIDs less than 5 days before procedure, and 
hemoglobin <11 g/dl and platelets <150.000/mmc.24 
PRP Preparation—110 ml of venous blood was collected from the patients a few hours 
before the procedure, it was then centrifuged and activated in the laboratory.24 
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PRP Injection—Prior to PRP injection, US-guided scarification was performed on the 
degenerated region of the tendon using a 21G needle to produce a small amount of 
bleeding.  The same needle was then reused to administer 6ml of the autologous PRP 
preparation into the degenerated region under US-guidance. Two treatments were 
performed at a mean distance of 3 ± 0.52 weeks.24  
Post Injection Protocol—Patients were to minimize physical activity for 48 hours after 
the injection with a gradual return to activity with the aide of physical therapy.24 
Patient Outcomes—Statistically significant improvement was seen in VISA-P at the 6 
month point, but not at the 20 day post procedure follow-up.  VISA-P at baseline, 20 
days, and 6 months was 56, 60, and 74, respectively.  The authors note that there were no 
complications during or after the procedure.24 
DISCUSSION 
 Jumper’s knee is a common condition in active individuals due to overuse.  To 
date, non-operative conservative treatment methods such as rest, ice, NSAIDs, injections, 
and eccentric exercises have all been used with varying degrees of success.  New 
therapies, such as PRP are directed at supporting the body’s own reparative process to 
obtain complete regeneration.24  The lack of reported side effects, ease of preparation and 
minimally invasive aspect of the procedure are just a few of the promising features of this 
treatment.19    
Each of the studies21-24 showed that PRP is an effective treatment for patellar 
tendinopathy, but the magnitude of the treatment effect is inconsistent. See Figure I. 
Vetrano et al21 were able to prove that PRP is superior to ESWT treatment at 6 and 12 
months follow-up.  The percentage of patients who were also satisfied with the PRP 
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compared with ESWT was also much higher at those follow-up dates.  The only other 
study to have two separate treatment groups was Gosens et al,23 who compared patients 
that had previously been treated with cortisone, ethoxysclerol, and/or surgery prior to 
PRP treatment and those who had not received any injections or surgical treatment.  The 
patients who had not been previously treated showed a larger improvement and thus, a 
greater healing potential.   Filardo et al22 found that patients with bilateral tendinopathy 
and also patients who had longer symptom duration appeared to have lower 
improvements. These observations imply that future research should focus on PRP 
interventions being used earlier. 
In fact, when PRP therapy is used in other tendinopathies, this approach has not 
consistently demonstrated superiority to other approaches. A recent RCT conducted on 
the supraspinatus by Rha et al25 compared PRP injection vs dry needing.  The authors 
noted that the range of motion between the two groups was equal, but the PRP provided 
greater symptomatic relief and functional improvement at six-month follow-up.  
However, two recent RCT26,27 comparing PRP to saline injections conducted on the 
Achilles tendon did not show any greater improvement. 
To date, there are at least 16 commercially available PRP preparation systems 
available for practitioners to choose from.  Systems vary in the amount of whole blood 
collected, final PRP obtained, total PRP concentration, and whether or not an activator is 
used.16  While each of the studies21-24 reported a positive effect, each prepared and 
administered differing amounts of PRP to their patients.  Vetrano et al21 administered 2ml 
of PRP after a single centrifuge of 1500 rpm X 10 minutes with no added activator.  
Filardo et al22 injected 5ml after two centrifugations of 1480 rpm X 6 minutes and 3400 
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rpm X 15 minutes.  Two of the samples had 10% calcium chloride added as an activator 
that had been stored at -30C and then thawed in a dry thermostat at 37C for 30 min prior 
to injection.  Gosens et al23 injected 1ml into the area of maximal tenderness while 
another 2ml was administered with a “peppering” technique.  Ferrero et al24 administered 
6ml PRP, but did not mention how the PRP was prepared.  In addition to the amount of 
PRP injected, the number of injections and the timing of the injections also varied from 
study to study.  Gosens et al23 and Ferrero et al24 utilized single injections.  Vetrano et 
al21 administered two injections one week apart, while Filardo et al22 injected three times 
with two weeks in between injections.    It is interesting to note that Gosens et al23 were 
the only study not to perform their injection under US guidance.  See Table II. These 
different approaches could confound the results. 
These studies21-24 had several limitations.  Mainly, all four had precision issues as 
they were conducted on small sample sizes. More specifically, Vetrano et al21 lacked 
blinding and quantitative measures like the use of ultrasound measured outcomes. Lastly, 
a more directly relevant comparison between treatment and a control group is lacking. 
This results in an overall very low quality of evidence. See Table I. 
CONCLUSION 
 The use of platelet-rich plasma injections for the treatment of patellar 
tendinopathy may be an effective treatment for reducing pain and improving function 
related to sport activity.  PRP has the potential to limit down time for patient’s and allow 
for earlier return to training and competition.  The aforementioned studies used various 
techniques as well as varying amount of PRP to treat patellar tendinopathy, yet they all 
showed improvements in VISA-P.  Patients with bilateral tendinopathy and those who 
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had previously been treated with injections or surgical procedures had lower rates of 
improvement.  The potential advantages of PRP outweigh the risks at this time.  No side 
effects of the treatments were listed, and because the preparation is autologous, risk of 
infection is low.   
 The overall quality of evidence for these studies is very low.  In order for PRP to 
become a proven treatment for tendon injuries, well-designed prospective randomized 
control trials must be conducted with long-term follow-up.  Specific attention should also 
be focused on timing of treatment, number and amount of doses, and the actual 
preparation of the PRP. 
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Table I. Characteristics of Reviewed Studies, GRADE profile 
 
Study  Year Study Design 
No of 
Patients Intervention 
Follow 
Up 
VISA-P mean 
(SD) Conclusion 
Quality of 
evidence 
      Baseline Final   
Vetrano 
et al21 2013 RCT 
PRP 
group 23 
Two injections 
US guided over 
two weeks 2 months, 
6 months, 
and 12 
months 
55.3 
(14.3) 
91.3 
(9.9) PRP greater 
effect than  
ESWT over 12 
months 
Low  
due to small 
sample size, 
lack of 
blinding, 
and failure 
to utilize 
quantitative 
measures 
ESWT 
group 23 
Three sessions 
of focused 
extracorporeal 
shock wave 
therapy 
56.1 
(19.9) 
77.6 
(19.9) 
Filardo et 
al22 2013 
Prospective 
Cohort 43 
Three US 
guided 
injections two 
weeks apart 
2 months, 
6 months, 
and 48 
months 
44.1 
(15.6) 
84.3 
(21.6) Positive effect 
Very low 
Due to small 
sample size 
and lack of a 
comparison 
group 
Gosens 
et al23 2012 
Prospective 
Cohort 
Group 
1 14 
Single injection 
Mean 
follow up 
18.4 
months 
41.8 
(14.3) 
56.3 
(26.2) Greater effect 
for those with 
no previous 
interventions  
Very low 
Due to small 
sample size 
and failure 
to utilize US 
guided 
injection 
Group 
2 22 
39.1 
(16.6) 
58.6 
(25.4) 
Ferrero 
et al24 2012 
Prospective 
Cohort 24 
Two injections 
three weeks 
apart under US 
guidance 
20 days 
and 6 
months 
56 
(18) 
74 
(14) Some effect 
Very low 
Due to small 
sample size 
and lack of a 
comparison 
group 
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Table II. Comparison of Each Study’s Injection Approach 
 
Study  Year 
PRP 
injection 
(ml) 
No of Injections Time Between Injections US Guidance Activator PRP System 
Vetrano et al21 2013 2ml 2 1 week apart Yes - 
MyCells Autologus 
Plate Preparation 
System (Kaylight ltd, 
Ramat-Hasharon, 
Israel) 
Filardo et al22 2013 5ml 3 2 weeks apart Yes 
10% Calcium-
chloride added to 2nd 
and 3rd injections 
prior to 
administration 
- 
Gosens et al23 2012 3ml 1 - - - 
Recover System 
(Biomet Biologics, 
Warsaw, Indiana) 
Ferrero et al24 2012 6ml 1 - Yes - - 
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Figure I. VISA-P Results 
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Appendix. VISA-P Questionnaire 
 
1. For how many minutes can you sit pain free? (from 0 min to 100 min) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
2. Do you have pain walking downstairs with a normal gait cycle? (from strong severe pain to no 
pain) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
3. Do you have pain at the knee with full active non-weight bearing knee extension? (from strong 
severe pain to no pain) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
4. Do you have pain when doing a full weight bearing lunge? (from strong severe pain to no pain) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
5. Do you have problems squatting? (from unable to no problems) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
6. Do you have pain during or immediately after doing 10 single leg hops? ( from strong sever 
pain/unable to no pain) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
7. Are you currently undertaking any sport or other physical activity? 
0 Not at all 
4 Modified training +/- competition 
7 Full training +/- competition but not at same level 
10 Competing at the same or higher level  
 
8. Complete EITHER A, B, or C in this question 
 
*     If you have no pain while undertaking sport complete Q8a only 
 
• 8a.     For how long can you train/practice? 
0 min 1-5 
min 
6-10 
min 
7-15 
min 
>15 
min 
0 
points 
7 
points 
14 
points 
21 
points 
30 
points 
 
*     If you have pain while undertaking sport, but it does not stop you from completing 
the activity, please complete Q8b only 
 
• 8b.     For how long can you train/practice? 
0 min 1-5 
min 
6-10 
min 
7-15 
min 
>15 
min 
0 
points 
4 
points 
10 
points 
14 
points 
20 
points 
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*     If you have pain that stops you from completing sport activities, please complete Q8c 
only 
 
• 8c.     For how long can you train/practice? 
0 min 1-5 
min 
6-10 
min 
7-15 
min 
>15 
min 
0 
points 
2 
points 
5 
points 
7 
points 
10 
points 
 
TOTAL VISA-P SCORE 
 
